Nolato (OM:NOLA B) Reports Higher Sales And Lower Earnings, Is It Still Undervalued?

Nolato (OM:NOLA B) is back in focus after its second quarter 2026 report, which showed slightly higher sales but lower net income and earnings per share compared with the same period last year.

See our latest analysis for Nolato.

Nolato’s recent earnings release appears to have weighed on sentiment, with the share price down 18.91% year to date and the 1 year total shareholder return declining 14.43%. However, the 3 year total shareholder return remains positive at 23.55%.

If you are reassessing Nolato after these results, it can help to see what else the market is rewarding right now by checking out 106 top founder-led companies

Nolato’s shares have slid while earnings have softened, so the balance between risk and potential reward has clearly shifted. Does the current valuation still justify backing the stock after this pullback?

Most Popular Narrative: 23.9% Undervalued

On the most followed narrative, Nolato’s fair value of SEK63.67 sits well above the last close at SEK48.45. That gap rests on some clear growth and margin expectations priced into the model.

Accelerating global healthcare expenditure and an aging population are fueling Nolato's Medical Solutions growth, underpinned by expansion into high-volume and high-margin segments like drug delivery systems and in-vitro diagnostics, supporting sustained increases in revenue and probable upward pressure on operating margins.

Read the complete narrative.

Curious what sits behind that valuation gap. The narrative leans on steady revenue expansion, firmer margins and a future earnings multiple that is not extreme by sector standards.

Result: Fair Value of SEK63.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Nolato still faces the risk that high expansion CapEx is not matched by demand, and that overcapacity and cyclical end markets keep margins under pressure.

Find out about the key risks to this Nolato narrative.

Next Steps

Given the mixed mood around Nolato, it makes sense to check the underlying data yourself and decide how the balance of risks and rewards looks to you. To get a clearer view of both sides of the story, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Nolato?

If Nolato has you rethinking your portfolio, do not stop here. Use the Simply Wall Street Screener to quickly surface other stocks that might better fit your goals.

• Target resilient opportunities by checking companies highlighted in the 304 resilient stocks with low risk scores that may better balance potential returns with measured risk.
• Spot potential future standouts early and review the screener containing 516 high quality undiscovered gems before the wider market pays closer attention.
• Strengthen your core holdings by reviewing stocks featured in the solid balance sheet and fundamentals stocks screener (422 results) that pair financial resilience with sound fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com